“…Despite the efficiency in neutralizing the systemic effects and the key contribution to reducing the number of deaths, antivenoms show some relevant limitations, such as adverse reactions, need for a specialized professional, cold chain, and batch variations. Some studies on Latin American antivenoms, including INS-COL (Colombia), PROBIOL (Colombia), ICP (Costa Rica), INS-PERU (Peru), UCV (Venezuela), BIOL (Argentina), FDTAV (Brazil), IVB (Brazil) and LBAV (Brazil) have demonstrated efficacy in neutralizing local effects under the preincubation protocol [ 8 , 9 ]. However, other investigations that addressed the preclinical efficacy of antivenoms via a challenge-then-treat model of envenoming have shown a low neutralization of these typical damages with significant improvements when a plant extract is used as a complementary therapy [ 10 ].…”